Last reviewed · How we verify

DE-117 Ophthalmic Solution QD — Competitive Intelligence Brief

DE-117 Ophthalmic Solution QD (DE-117 Ophthalmic Solution QD) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline.

phase 2 Small molecule Live · refreshed every 30 min

Target snapshot

DE-117 Ophthalmic Solution QD (DE-117 Ophthalmic Solution QD) — Santen Inc.. DE-117 is a selective EP2 receptor agonist that lowers intraocular pressure through increased uveoscleral outflow.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
DE-117 Ophthalmic Solution QD TARGET DE-117 Ophthalmic Solution QD Santen Inc. phase 2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). DE-117 Ophthalmic Solution QD — Competitive Intelligence Brief. https://druglandscape.com/ci/de-117-ophthalmic-solution-qd. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing